CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In the case of the GSE218183 dataset, primary CD34+ CML cells isolated from peripheral blood of three unrelated chronic phase CML patients were treated with nilotinib (3 μM), idasanutlin (166 nM), or a combination for 24 hrs or 72 hrs; thereafter, RNA-seq analysis was performed (nilotinib treated n = 3, idasanutlin treated n = 2, idasanutlin + nilotinib treated n = 3, untreated n = 3).